Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- Hitting Home Runs & Grand Slams, Not Loud Outs
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Aggressive Growth Stocks
- Who Wants to Keep "Too Big to Fail" Alive?
- Debt-Ceiling Alarm Bell Tolls
- Avoid These 3 Eurozone ETFs This Summer
- RTI: When Will We Finally See a Pullback?
- Top Stocks with Big Potential Catch-Up Moves
- AWS 5/22: Will Bernanke Show His Hand?
- PFP 5/22: Singular Stock Focus Continues
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/22/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 9.31% |
| SONIC FOUNDR | SOFO | 7.77% |
| VELTI PLC OR | VELT | 7.58% |
| TRI TECH HOL | TRIT | 6.62% |
| A M R CP | AAMRQ | 4.52% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
BioMarin Pharmaceutical Inc. ( BMRN - Analyst Report ) recently announced the completion of a phase I study, which evaluated its candidate BMN-111 in men (above 18 years) suffering from achondroplasia. Achondroplasia refers to the commonest form of dwarfism in humans. The double-blind, placebo-controlled study was initiated in February this year.
The study consisted of two parts. While the first part of the study was evaluating a chain of single subcutaneous doses, the second part included either ten days of fixed dosing or dose escalation.
Results from the study showed that BMN-111, an analog of C-type Natriuretic Peptide (CNP), was well tolerated. The adverse events observed in the study were mild in nature.
BioMarin now plans to initiate a proof-of-concept and dose finding phase II study on the candidate in mid-2013. The primary objective of the study will be to assess growth velocity along with medical complications of achondroplasia.
We note that BioMarin recently announced preliminary results from a phase II program of PEG-PAL (PEGylated recombinant Phenylalanine Ammonia Lyase), which is being developed to treat phenylketonuria (PKU). The company plans to initiate a phase III study of PEG-PAL in the second quarter of 2013.
The company has multiple data readouts lined up in the near future. BioMarin is expecting results from the much awaited phase III trial of GALNS in the fourth quarter of 2012. The candidate is being developed as an enzyme replacement therapy (ERT) for the treatment of lysosomal storage disorder mucopolysaccharidosis type IVA (MPS IVA). The company is also expecting results from a phase I/II trial of BMN-673 (solid tumors) in the same quarter.
Our Recommendation
We have a Neutral recommendation on BioMarin, which carries a Zacks #3 Rank (Hold) in the short run. We expect investor focus to stay on the results of the upcoming data readouts.
Read the full Analyst Report on BMRN